Ask HopeStage to review this study with me
Study ID: NCT05211947. We help you review the study, but cannot decide medical eligibility.
TerminatedNCT05211947
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
This study has public registry information in the United States, in Australia, in France, .... It focuses on schizophrenia.
SchizophreniaDrugFrom 18 Years to 51 Years
Key information made simple
What is this study testing?
This study is testing whether a study medication may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive a study medication, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in Argentina, Australia, Austria.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
The official record suggests in-person participation through a hospital, with sites including Advanced Research Center, Inc in Anaheim, Clinical Innovations, Inc in Bellflower, and ProScience Research Group in Culver City. Participation appears to involve a study treatment together with follow-up visits and routine safety or progress checks. The main fit is usually being able to understand the study and consent and matching the main diagnosis, while common reasons not to take part include safety concerns that need urgent care first and active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means a larger group and a closer look at how well the approach holds up.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
Study start dateStarted: March 21, 2022
- Recruitment status
- Terminated
- Estimated enrollment
- Not clearly listed
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Not clearly listed
- Locations
- United States, Australia, France, ...
- Age range
- From 18 Years to 51 Years
- Official registry ID
- NCT05211947
- Official title
- A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
- Official source
- Official registry link
Want help reviewing this study?
Study ID: NCT05211947. We help you review the study, but cannot decide medical eligibility.
For you
Taking part may give access to a new approach being evaluated.
It requires regular visits and structured follow-up.
Requires travel, with in-person participation in Argentina.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.
Do I need to want to stop or reduce tobacco use to participate?
The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Boehringer Ingelheim, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study is not currently recruiting. Check the official registry for the reason and latest status.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
TerminatedNCT04109950
Safety study of an Investigational Drug in schizophrenia
This study has public registry information in the United States, in Bulgaria, in Colombia, .... It is testing an Investigational Drug for schizophrenia.
TerminatedNCT05359081
A study Long-term Safety and Tolerability of SEP-363856 in people with Schizophrenia in Japan
This study has public registry information. It focuses on schizophrenia and currently lists study information in Japan.
TerminatedNCT01328093
A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients
This study has public registry information. It focuses on schizophrenia and currently lists study information in Austria, Belgium, France, Germany, Poland, the United States, Romania, Spain, and Sweden.